4.2.3. Effects of SGLT2 Inhibitors on Metabolite Excretion, Lipid Profiles, and Gut Microbiota in Type 2 Diabetes and Atherosclerosis. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.